Close Menu

NEW YORK – Centogene said on Tuesday that it is teaming up with Alnylam Pharmaceuticals on a clinical biomarker study of hereditary transthyretin-related amyloidosis (ATTRv).

The study, called TRAMmoniTTR, will longitudinally monitor the clinical status of both symptomatic and asymptomatic participants with variants in the TTR gene, which encodes transthyretin, formerly known as prealbumin. Mutated Ttr proteins get misfolded, which results in transthyretin amyloidosis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Nature News writes that scientists are trying to figure out how to name the new strains of SARS-CoV-2 that are emerging.

The New York Times reports that researchers are studying identical twins who had COVID-19 to understand the influence of genetics on disease severity.

In PNAS this week: epistasis affecting cystic fibrosis, Tiger rattlesnake genome gives venom insight, and more.